PMID- 32293191
OWN - NLM
STAT- MEDLINE
DCOM- 20200604
LR  - 20240405
IS  - 1748-880X (Electronic)
IS  - 0007-1285 (Print)
IS  - 0007-1285 (Linking)
VI  - 93
IP  - 1110
DP  - 2020 Jun
TI  - Mid-position treatment strategy for locally advanced lung cancer: a dosimetric 
      study.
PG  - 20190692
LID - 10.1259/bjr.20190692 [doi]
LID - 20190692
AB  - OBJECTIVE: The internal target volume (ITV) strategy generates larger planning 
      target volumes (PTVs) in locally advanced non-small cell lung cancer (LA-NSCLC) 
      than the Mid-position (Mid-p) strategy. We investigated the benefit of the Mid-p 
      strategy regarding PTV reduction and dose to the organs at risk (OARs). METHODS: 
      44 patients with LA-NSCLC were included in a randomized clinical study to compare 
      ITV and Mid-p strategies. GTV were delineated by a physician on maximum intensity 
      projection images and on Mid-p images from four-dimensional CTs. CTVs were 
      obtained by adding 6 mm uniform margin for microscopic extension. CTV to PTV 
      margins were calculated using the van Herk's recipe for setup and delineation 
      errors. For the Mid-p strategy, the mean target motion amplitude was added as a 
      random error. For both strategies, three-dimensional conformal plans delivering 
      60-66 Gy to PTV were performed. PTVs, dose-volume parameters for OARs (lung, 
      esophagus, heart, spinal cord) were reported and compared. RESULTS: With the 
      Mid-p strategy, the median of volume reduction was 23.5 cm(3) (p = 0.012) and 
      8.8 cm(3) (p = 0.0083) for PTV(T) and PTV(N) respectively; the median mean lung 
      dose reduction was 0.51 Gy (p = 0.0057). For 37.1% of the patients, delineation 
      errors led to smaller PTV with the ITV strategy than with the Mid-p strategy. 
      CONCLUSION: PTV and mean lung dose were significantly reduced using the Mid-p 
      strategy. Delineation uncertainty can unfavorably impact the advantage. ADVANCES 
      IN KNOWLEDGE: To the best of our knowledge, this is the first dosimetric 
      comparison study between ITV and Mid-p strategies for LA-NSCLC.
FAU - Ayadi, M
AU  - Ayadi M
AD  - Radiotherapy and Physics Department, Leon Berard Cancer Center, 28, rue Laennec 
      F-69373, Lyon, France.
FAU - Baudier, T
AU  - Baudier T
AD  - Univ Lyon, INSA-Lyon, Universite Lyon 1, CNRS, Inserm, Centre Leon Berard, 
      CREATIS UMR 5220, U1206, F-69373, Lyon, France.
FAU - Bouilhol, G
AU  - Bouilhol G
AD  - Department of Radiotherapy, Hartmann Radiotherapy Center, American Hospital of 
      Paris, Neuilly, France.
FAU - Dupuis, P
AU  - Dupuis P
AD  - Radiotherapy and Physics Department, Leon Berard Cancer Center, 28, rue Laennec 
      F-69373, Lyon, France.
FAU - Boissard, P
AU  - Boissard P
AD  - Radiotherapy and Physics Department, Leon Berard Cancer Center, 28, rue Laennec 
      F-69373, Lyon, France.
FAU - Pinho, R
AU  - Pinho R
AD  - Univ Lyon, INSA-Lyon, Universite Lyon 1, CNRS, Inserm, Centre Leon Berard, 
      CREATIS UMR 5220, U1206, F-69373, Lyon, France.
FAU - Krason, A
AU  - Krason A
AD  - Univ Lyon, INSA-Lyon, Universite Lyon 1, CNRS, Inserm, Centre Leon Berard, 
      CREATIS UMR 5220, U1206, F-69373, Lyon, France.
FAU - Rit, S
AU  - Rit S
AD  - Univ Lyon, INSA-Lyon, Universite Lyon 1, CNRS, Inserm, Centre Leon Berard, 
      CREATIS UMR 5220, U1206, F-69373, Lyon, France.
FAU - Claude, L
AU  - Claude L
AD  - Radiotherapy and Physics Department, Leon Berard Cancer Center, 28, rue Laennec 
      F-69373, Lyon, France.
FAU - Sarrut, D
AU  - Sarrut D
AD  - Univ Lyon, INSA-Lyon, Universite Lyon 1, CNRS, Inserm, Centre Leon Berard, 
      CREATIS UMR 5220, U1206, F-69373, Lyon, France.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200415
PL  - England
TA  - Br J Radiol
JT  - The British journal of radiology
JID - 0373125
SB  - IM
MH  - Aged
MH  - Brachial Plexus/diagnostic imaging/radiation effects
MH  - Carcinoma, Non-Small-Cell Lung/diagnostic imaging/pathology/*radiotherapy
MH  - Esophagus/diagnostic imaging/radiation effects
MH  - Four-Dimensional Computed Tomography
MH  - Heart/diagnostic imaging/radiation effects
MH  - Humans
MH  - Lung/diagnostic imaging/radiation effects
MH  - Lung Neoplasms/diagnostic imaging/pathology/*radiotherapy
MH  - *Organ Motion
MH  - Organs at Risk/diagnostic imaging/radiation effects
MH  - Prospective Studies
MH  - Radiation Injuries/prevention & control
MH  - Radiotherapy Dosage
MH  - Radiotherapy Planning, Computer-Assisted
MH  - Radiotherapy, Conformal/methods
MH  - *Respiration
MH  - Spinal Cord/diagnostic imaging/radiation effects
MH  - Tumor Burden
PMC - PMC10993224
EDAT- 2020/04/16 06:00
MHDA- 2020/06/05 06:00
PMCR- 2021/04/16
CRDT- 2020/04/16 06:00
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2020/06/05 06:00 [medline]
PHST- 2020/04/16 06:00 [entrez]
PHST- 2021/04/16 00:00 [pmc-release]
AID - bjr.20190692 [pii]
AID - 10.1259/bjr.20190692 [doi]
PST - ppublish
SO  - Br J Radiol. 2020 Jun;93(1110):20190692. doi: 10.1259/bjr.20190692. Epub 2020 Apr 
      15.